ClinicalTrials.gg
CompletedNCT02508064Updated Sep 11, 2017

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

A Phase 1 interventional study of BMS-663068 in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This 2-part study will determine the bioavailability of BMS-626529 in healthy subjects from prototype low dose extended release formulations (Part 1) of BMS-663068 and prototype extended release multi-particulate formulations (Part 2) of BMS-663068 relative to 600 mg extended release tablet of BMS-663068.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 27 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Males and females, 18 to 50 years of age, inclusive
  • Healthy subjects as determined by no deviation from normal in medical and surgical history, PE findings, vital sign measurements, 12-lead measurements, physical measurements, and clinical laboratory test results
  • Women of (WOCBP) must have a negative urine pregnancy test (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study drug

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Evidence of organ dysfunction or any deviation from normal in PE, vital signs, , or clinical laboratory determinations beyond what is consistent with the target population
  • Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat:

    i) PR ≥ 210 msec ii) QRS ≥ 120 msec iii) ≥ 500 msec and iv) QTcF ≥ 450 msec

  • Exposure to any drug or placebo within 12 weeks of study drug administration
  • Positive blood screen for antibody (HCV Ab), surface antigen (HBsAg), or -1 and HIV-2 antibody
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Part 1

    BMS-663068 1 × 600 mg extended-release (ER) tablet formulation

    Drug: BMS-663068

  • Experimental
    Part 1: Prototype 1

    BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)

    Drug: BMS-663068

  • Experimental
    Part 1: Prototype 2

    BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)

    Drug: BMS-663068

  • Experimental
    Part 1: Prototype 3

    BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)

    Drug: BMS-663068

  • Experimental
    Part 1: Prototype 4

    BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)

    Drug: BMS-663068

  • Experimental
    Part 1: Prototype 5

    BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)

    Drug: BMS-663068

  • Experimental
    Part 2

    BMS-663068 1 × 600 mg ER tablet formulation

    Drug: BMS-663068

  • Experimental
    Part 2: Prototype 1

    BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)

    Drug: BMS-663068

  • Experimental
    Part 2: Prototype 2

    BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)

    Drug: BMS-663068

  • Experimental
    Part 2: Prototype 3

    BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)

    Drug: BMS-663068

  • Experimental
    Part 2: Prototype 4

    BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)

    Drug: BMS-663068

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) of BMS-626529

    Time frame: Day 1 to Day 4 of each period

  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of BMS-626529

    Time frame: Day 1 to Day 4 of each period

  3. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-626529

    Time frame: Day 1 to Day 4 of each period

Secondary outcomes

  1. Safety of BMS-663068 will be measured by incidence of Adverse events (AEs), Serious adverse events (SAEs), and AEs leading to discontinuation;, and results of clinical laboratory tests, vital signs, 12-lead ECGs, and Physical examination (PE)

    Time frame: Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing

  2. Tolerability of BMS-663068 will be measured by incidence of AEs, SAEs, and AEs leading to discontinuation; and results of clinical laboratory tests, vital signs and 12-lead ECGs

    Time frame: Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing

07

Study locations

1 site
  • GSK Investigational Site
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Nov 2015, 3 months.

Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2015
First posted
Jul 24, 2015
StartActual
Aug 3, 2015
Primary completionActual
Nov 5, 2015
CompletionActual
Nov 5, 2015
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02508064
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 24, 2015
Start date
Aug 3, 2015
Primary completion
Nov 5, 2015
Completion
Nov 5, 2015
Last update
Sep 11, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostemsavir

Start the discussion